Skip to content

Utilisation de la kétamine en psychiatrie : mise à jour

Marie-Thérèse Clerc, Marcus Rosenhagen-Lapoirie, Armin Von Gunten

Revue Médicale Suisse 2022 DOI: 10.53738/revmed.2022.18.793.1626 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Review Peer reviewed
Intervention Ketamine
Key findings The authors report that low-dose ketamine has a rapid, robust antidepressant effect via a mechanism different from conventional treatments, is included in several international recommendations for treatment-resistant depression, and is generally given intravenously or intranasally in outpatient or inpatient settings when safety requirements are met. They argue ketamine is a promising, innovative treatment, with growing interest in its use for other resistant psychiatric disorders such as anxiety and substance use disorders.

Abstract

Ketamine has demonstrated at a lower dose a robust and rapid antidepressant effect due to a mechanism of action different from conventional treatments. It is now included in several international recommendations on treatment-resistant depression. Ketamine may be used in both out- or in-patient settings, generally by way of intravenous or intranasal formulations provided the fulfillment of safety requirements. There is a growing interest in the use of ketamine for other resistant psychiatric disorders such as anxiety and substance use disorders. Ketamine proves an innovating and promising treatment that extends the range of therapeutic possibilities in psychiatry. We propose here to review its current clinical use.

Citations in the library

Explore topics